Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | PPP3CB | P16298 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10266429 | 1.00 | CYP3A4 (0.44) | CYP3A4CTSBPPP3CBCTSS | |
| SCHEMBL3478868 | 1.00 | CYP3A4 (0.44) | CYP3A4CTSBPPP3CBCTSS | |
| SCHEMBL3478894 | 1.00 | CYP3A4 (0.44) | CYP3A4CTSBPPP3CBCTSS | |
| SCHEMBL3478907 | 0.94 | CYP3A4 (0.38) | CYP3A4CTSBPPP3CBCTSS | |
| SCHEMBL3478883 | 0.93 | CYP3A4 (0.52) | CYP3A4CTSBPPP3CBCTSS | |
| SCHEMBL3478892 | 0.92 | CTSS (0.39) | CYP3A4CTSBPPP3CBCTSS | |
| SCHEMBL3431431 | 0.92 | CTSS (0.39) | CYP3A4CTSBPPP3CBCTSS | |
| SCHEMBL3478904 | 0.91 | CYP3A4 (0.37) | CYP3A4CTSBPPP3CBCTSS | |
| SCHEMBL10265789 | 0.91 | CYP3A4 (0.37) | CYP3A4CTSBPPP3CBCTSS | |
| SCHEMBL3478896 | 0.91 | CTSS (0.39) | CYP3A4CTSBPPP3CBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2012040242-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | VIP, EIF2AK2, PREP | CYP3A4 1213/4885CTSB 374/4885PPP3CB 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.